Abstract
The aim of this study was to prospectively assess the safety and efficacy of lovastatin in the treatment of cholesteryl ester storage disease in siblings who were ages 11.6 and 5 y at the beginning of treatment. Mean total and LDL cholesterol in the male proband, 7.40 and 5.68 mmol/L, respectively, on diet alone, fell 30% to 5.2 (p ≤ 0.001) and 31% to 3.9 mmol/L (p ≤ 0.001) on lovastatin 40 mg/d over 3.3 y, with simultaneous resolution of hepatosplenomegaly. In his sister, on lovastatin 20 mg/d for 1.5 y, total and LDL cholesterol fell, but not significantly; her hepatosplenomegaly was also reduced on treatment. Lovastatin was well tolerated without overt side effects or complications and without adverse changes in liver function tests or creatine phosphokinase. Normal and expected accretion of height and weight occurred during the treatment period for both children. Lovastatin appears to be a safe and effective treatment for pediatric cholesteryl ester storage disease.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Glueck, C., Lichtenstein, P., Tracy, T. et al. Safety and Efficacy of Treatment of Pediatric Cholesteryl Ester Storage Disease with Lovastatin. Pediatr Res 32, 559–565 (1992). https://doi.org/10.1203/00006450-199211000-00015
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1203/00006450-199211000-00015
This article is cited by
-
Cholesterol Ester Storage Disease (CESD) Diagnosed in an Asymptomatic Adult
Digestive Diseases and Sciences (2009)
-
Treatment of dyslipidemia with lovastatin and ezetimibe in an adolescent with cholesterol ester storage disease
Lipids in Health and Disease (2005)
-
Statins in children: What do we know and what do we need to do?
Current Atherosclerosis Reports (2001)
-
Cholesteryl Ester Storage Disease: Case Report during Childhood
Pediatric and Developmental Pathology (1999)